Loading…
Loading…
EQUITY / NASDAQ · XNGS
YD Bio Limited
No accepted understanding yet. Follow this company to establish research where evidence supports it.
Open research workspace →01/01/2025 – 12/31/2025 · USD · Units
Reported figures establish facts for this period; they do not by themselves establish a profitability trend.
Open report ↗7.18 USD · 0.9845%
Observed: Oct 5, 2026, 9:19 PM · TickerLayer indicative price; may be delayed
Powered by TickerLayer
10/05/2026 · 7.11 USD · Volume 258,547
276 actual observations · Latest bar: 2026-10-05 · Market data is indicative; provider terms apply.
3 available financial reports
Research reports →SEC FINANCIAL REPORTS
01/01/2025 – 12/31/2025 · Units
| Metric | 2025 / Year end | 2024 / Year end | Change |
|---|---|---|---|
| Revenue | 596,817 USD | 510,360 USD | +16.94% |
| Operating profit | -5,271,721 USD | -1,461,930 USD | — |
| Net income | -8,311,316 USD | -1,411,559 USD | — |
| Operating cash flow | -6,596,706 USD | -1,222,681 USD | — |
| Cash and cash equivalents | 6,007,615 USD | 3,132,298 USD | +91.80% |
Changes are calculated only for matching period length, consolidation, currency, and scale. Percentages are not shown for zero or negative baselines.
Each column uses its report's scale. Check column headers before comparing different consolidation scopes and scales.
| Financial metric | 2025 / Year end01/01/2025 – 12/31/2025ConsolidatedUnits · USD | 2024 / Year end01/01/2024 – 12/31/2024ConsolidatedUnits · USD | 2023 / Year end01/01/2023 – 12/31/2023ConsolidatedUnits · USD |
|---|---|---|---|
| Capital expendituresCash flow statement | 1,440,019 USD | 74,914 USD | 290 USD |
| Cash and cash equivalentsBalance sheet | 6,007,615 USD | 3,132,298 USD | — |
| Financing cash flowCash flow statement | 10,869,150 USD | 7,113,509 USD | 113,887 USD |
| Gross profitIncome statement | 167,410 USD | 155,356 USD | 153,445 USD |
| Investing cash flowCash flow statement | -1,440,019 USD | -2,900,670 USD | -290 USD |
| Net incomeIncome statement | -8,311,316 USD | -1,411,559 USD | 13,560 USD |
| Operating cash flowCash flow statement | -6,596,706 USD | -1,222,681 USD | -55,657 USD |
| Operating profitIncome statement | -5,271,721 USD | -1,461,930 USD | -9,847 USD |
| RevenueIncome statement | 596,817 USD | 510,360 USD | 350,131 USD |
| Total assetsBalance sheet | 13,779,397 USD | 6,864,226 USD | — |
| Total equityBalance sheet | -2,855,663 USD | 6,590,246 USD | 22,994 USD |
| Total liabilitiesBalance sheet | 16,635,060 USD | 273,980 USD | — |
| Report source | Open report ↗ Published: 04/30/2026 | Open report ↗ Published: 04/30/2026 | Open report ↗ Published: 04/30/2026 |
The latest available source version is shown for each period. Previous versions and correction relationships are not shown in this view.